Paras Pharma

Paras Biopharmaceuticals Finland Oy is a specialized biopharmaceutical company and Contract Development and Manufacturing Organization (CDMO) based in Oulu, Finland. The company focuses on the development of complex recombinant proteins and biosimilars using its proprietary expression and purification technologies, including the Diabrid and NobleCleav platforms. Their internal pipeline features biosimilar candidates for high-value biologics such as teriparatide, romiplostim, and anakinra, targeting indications in osteoporosis, hematology, and rheumatology. In addition to its own product development, Paras Biopharmaceuticals provides comprehensive services for microbial-based biologics production, from strain development to large-scale GMP manufacturing. The company serves a global clientele, offering expertise in overcoming challenges related to protein expression and efficient cleavage of fusion proteins.